Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epirubicin-Cyclophosphamide Followed by Taxanes or Taxanes Plus Carboplatin in Triple-Negative Breast Cancer：A Prospective, Randomized, Phase III Trial

NCT02455141 is registered in ClinicalTrials.gov with Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT02455141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02455141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epirubicin-Cyclophosphamide Followed by Taxanes or Taxanes Plus Carboplatin in Triple-Negative Breast Cancer：A Prospective, Randomized, Phase III Trial
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 31, 2016
Completion date
March 31, 2030
Enrollment
786 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm